Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Autolus Therapeutics plc as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 101
- −9 vs. Q2 2024
- Shares held
- 178.6M
- +4.92M (+2.8%) vs. Q2 2024
- Total value
- $648.5M
- +$43.9M (+7.3%) vs. Q2 2024
- New holders
- 7
- 31 more added
- Sold out
- 16
- 36 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AUTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 83 | $212.0M |
| Q1 2026 | 84 | $184.4M |
| Q4 2025 | 89 | $277.1M |
| Q3 2025 | 96 | $235.7M |
| Q2 2025 | 94 | $378.6M |
| Q1 2025 | 95 | $261.0M |
| Q4 2024 | 110 | $395.4M |
| Q3 2024 | 101 | $648.5M |
| Q2 2024 | 111 | $620.0M |
| Q1 2024 | 120 | $1.12B |
| Q4 2023 | 99 | $746.6M |
| Q3 2023 | 71 | $258.1M |
| Q2 2023 | 69 | $260.4M |
| Q1 2023 | 65 | $195.1M |
| Q4 2022 | 71 | $204.2M |
| Q3 2022 | 66 | $105.7M |
| Q2 2022 | 67 | $143.9M |
| Q1 2022 | 66 | $228.6M |
| Q4 2021 | 73 | $272.3M |
| Q3 2021 | 59 | $164.2M |
| Q2 2021 | 69 | $169.6M |
| Q1 2021 | 63 | $129.4M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Autolus Therapeutics plc; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wellington Management Group LLP | 24,220,226 | $87.9M | 0.02% | +6,330,392+35.4% | Added |
| Commodore Capital LP | 0 | $0 | 0.00% | −1,178,723−100.0% | Sold out |
| Exome Asset Management LLC | 0 | $0 | 0.00% | −839,472−100.0% | Sold out |
| Driehaus Capital Management LLC | 0 | $0 | 0.00% | −668,349−100.0% | Sold out |
| LGT Capital Partners Ltd. | 0 | $0 | 0.00% | −370,000−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −266,692−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −212,294−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −132,580−100.0% | Sold out |
| Rafferty Asset Management, LLC | 0 | $0 | 0.00% | −99,319−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −93,275−100.0% | Sold out |
| Allianz Asset Management GmbH | 0 | $0 | 0.00% | −38,700−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −27,395−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −22,242−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −20,589−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −10,262−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −10,111−100.0% | Sold out |
| Itau Unibanco Holding S.A. | 0 | $0 | 0.00% | −3,763−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |